Structured Follow-Up for Fever of Unknown Origin: Evidence-Based Approaches for Clinical Practice

Abstract

Fever of unknown origin (FUO) remains a challenging clinical syndrome, characterized by prolonged fever with no identifiable cause after standardized evaluation. This review synthesizes contemporary evidence and guideline-based recommendations on structured follow-up for FUO, incorporating epidemiological trends, underlying pathophysiological mechanisms, risk stratification, and diagnostic algorithms. The article emphasizes the importance of systematic, stepwise approaches in diagnosis and management, highlights recent advances in diagnostic technologies, and discusses clinical implications of emerging therapies. A multidisciplinary, patient-centered strategy is advocated to optimize outcomes and reduce morbidity associated with prolonged undiagnosed fever in adults and children.

Introduction

Fever of unknown origin (FUO) is defined as a temperature exceeding 38.3°C on several occasions, persisting for at least three weeks, and remaining undiagnosed after one week of inpatient investigation. Despite advances in diagnostic modalities, FUO persists as a perplexing problem for clinicians, often necessitating a systematic and structured approach to follow-up. The clinical spectrum of FUO is broad, encompassing infectious, neoplastic, inflammatory, and miscellaneous causes. Structured follow-up is critical to facilitate timely diagnosis, avoid unnecessary interventions, and improve patient outcomes. This review provides an evidence-based overview of structured follow-up strategies for FUO, integrating recent scientific advances and guideline recommendations.

Epidemiology / Disease Burden

FUO accounts for approximately 2–3% of hospital admissions for prolonged fever in developed countries, with a higher prevalence in resource-limited settings. The incidence has shifted over time, reflecting changes in epidemiology of infectious diseases, cancer, and autoimmune disorders. In adults, infections remain the most common etiology, followed by neoplastic and non-infectious inflammatory diseases (NIIDs). In pediatric populations, the burden of infectious causes is even higher. Despite extensive workups, up to 30% of FUO cases remain undiagnosed. The clinical and economic burden is substantial, with prolonged hospitalizations, diagnostic uncertainty, and associated healthcare costs.

Pathophysiology

The pathophysiology of FUO is multifactorial, reflecting the diverse underlying etiologies. Fever is a systemic response to pyrogenic cytokines, including interleukin (IL)-1, IL-6, tumor necrosis factor-alpha (TNF-α), and interferons, which influence the hypothalamic thermoregulatory center. In infectious FUO, endogenous and exogenous pyrogens drive sustained fever. In neoplastic and autoimmune cases, aberrant immune activation and cytokine release are predominant. Granulomatous diseases, lymphoproliferative disorders, and vasculitides can contribute via chronic inflammatory cascades. Understanding these mechanisms is crucial for tailoring diagnostic and therapeutic strategies during follow-up.

Risk Factors

Risk factors for FUO are largely dictated by demographic and clinical context. Advanced age, immunosuppression, underlying malignancy, travel to endemic regions, recent hospitalization, and exposure to zoonoses increase the risk of specific FUO etiologies. In pediatric patients, incomplete vaccination and congenital immunodeficiencies are notable risk factors. A thorough history encompassing occupational, social, and environmental exposures is essential to inform risk stratification and guide structured follow-up.

Clinical Features

FUO is clinically heterogeneous. While persistent fever is the hallmark, associated symptoms may include weight loss, night sweats, arthralgia, rash, lymphadenopathy, and organomegaly. The absence of focal signs often complicates diagnostic efforts. Temporal patterns of fever (intermittent, remittent, or continuous) may offer diagnostic clues. Systematic documentation of symptoms, physical findings, and laboratory trends is integral to effective follow-up, facilitating recognition of evolving clinical patterns that may point toward a diagnosis.

Diagnosis

The diagnostic approach to FUO is structured and stepwise, beginning with thorough history-taking, comprehensive physical examination, and initial laboratory testing (complete blood count, inflammatory markers, liver and renal function, urinalysis, blood cultures, imaging). If initial evaluation is unrevealing, second-tier investigations are tailored based on clinical suspicion and epidemiological context—examples include autoimmune panels, serologies, bone marrow biopsy, and advanced imaging (CT, MRI, PET-CT). Serial reassessment is critical; new signs or symptoms may emerge over time, guiding focused investigations. Multidisciplinary consultation (infectious diseases, rheumatology, oncology) is often warranted in persistent cases. Structured documentation and periodic re-evaluation are key elements of organized follow-up.

Treatment & Management

Empirical therapy is generally discouraged in FUO without a clear diagnosis, except in cases of clinical instability or high suspicion for life-threatening infection. Management is predominantly supportive—hydration, antipyretics, and symptomatic care. Structured follow-up involves regular reassessment, close monitoring for new clinical developments, and judicious use of diagnostic interventions. In immunocompromised patients or those with rapidly deteriorating status, empiric broad-spectrum antimicrobials may be justified while diagnostic efforts continue. Psychosocial support and patient education are essential to address anxiety and maintain adherence during prolonged evaluation.

Recent Advances / Emerging Therapies

Recent advances in diagnostic imaging, such as 18F-FDG PET/CT, have improved detection of occult infections, malignancies, and inflammatory foci in FUO. Molecular diagnostic techniques, including multiplex PCR and next-generation sequencing, enhance pathogen identification in culture-negative cases. Biomarkers such as procalcitonin and IL-6 assist in distinguishing infectious from non-infectious etiologies, informing targeted follow-up. Artificial intelligence and machine learning algorithms are being explored for pattern recognition and risk stratification, though clinical validation is ongoing. These innovations are reshaping the landscape of FUO evaluation and structured follow-up.

Guideline Recommendations

Major guidelines (e.g., Infectious Diseases Society of America, European Society of Clinical Microbiology and Infectious Diseases) endorse a structured diagnostic approach to FUO, emphasizing repeated clinical assessment, avoidance of indiscriminate testing, and individualized follow-up intervals. Routine empiric therapy is not recommended unless specific indications exist. Regular multidisciplinary case reviews and systematic documentation of clinical evolution are essential. Guidelines advocate for judicious use of advanced diagnostics, with escalation based on emerging clinical or laboratory evidence during structured follow-up.

Conclusion

Structured follow-up is foundational to the effective management of fever of unknown origin. A systematic, evidence-based approach that incorporates epidemiological context, risk stratification, and serial clinical reassessment optimizes diagnostic yield and patient outcomes. Recent advances in imaging and molecular diagnostics have enhanced the clinician\'s ability to identify elusive causes of FUO. Adherence to guideline-driven strategies, multidisciplinary collaboration, and patient-centered care are paramount. Ongoing research and technological innovation hold promise to further refine the structured follow-up of FUO, reducing the burden of undiagnosed prolonged fever in clinical practice.